Fig 1. CDK5 siRNA inhibits cell growth and enhances paclitaxel sensitivity in multiple ovarian cancer cell lines.

(A) Short term cell growth assay. Hey and A2780 cells in 96-well plates were reverse transfected with control siRNA or CDK5 siRNA (Dhamarcon) for 24 h and treated with 5 nM paclitaxel (Pac) or diluent (Control) for an additional 48 h. A crystal violet cell proliferation assay was used to measure the growth of cells. (B) Clonogenic and cell growth assays. HEY and A2780 cells were transfected with control siRNA or CDK5 siRNA for 24 h, and then cells were treated with diluent (Control) or 3 nM paclitaxel (Pac) for 14 days (clonogenic assay) or cells were treated with multiple concentrations of paclitaxel (Pac) or diluent (Control) for an additional 48 h (cell growth assays). The IC50s of paclitaxel with or with CDK5 siRNA treatment in Hey and A2780 cells were calculated in GraphPad.